Equities

N4 Pharma PLC

N4P:LSE

N4 Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.475
  • Today's Change0.0000000000000001 / 0.00%
  • Shares traded389.00k
  • 1 Year change-17.39%
  • Beta1.2866
Data delayed at least 20 minutes, as of Feb 06 2026 15:44 GMT.
More ▼

Profile data is unavailable for this security.

About the company

N4 Pharma plc is a United Kingdom-based pre-clinical biotech company. The Company is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The Company is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.

  • Revenue in GBP (TTM)7.07k
  • Net income in GBP-1.07m
  • Incorporated1979
  • Employees4.00
  • Location
    N4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
  • Phone+44 13 3269 0061Fax+44 12 7982 1300
  • Websitehttps://www.n4pharma.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Shortwave Life Sciences PLC45.70k-256.99k868.17k2.00868.17k2.00
Roquefort Therapeutics PLC0.00-882.45k1.96m1.001.96m1.00
ValiRx Plc49.78k-1.78m2.56m14.002.56m14.00
N4 Pharma PLC7.07k-1.07m3.95m4.003.95m4.00
TheraCryf PLC0.00-2.01m4.51m9.004.51m9.00
Ovoca Bio PLC0.0065.12k5.28m1.005.28m1.00
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Data as of Feb 06 2026. Currency figures normalised to N4 Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025373.25k0.05%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.